We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Unified Approach Could Prevent Unnecessary Blood Tests in PICU without Increasing Sepsis Risk

By LabMedica International staff writers
Posted on 03 May 2022
Print article
Image: Hospitals can avoid unnecessary blood draws in critically ill children (Photo courtesy of Unsplash)
Image: Hospitals can avoid unnecessary blood draws in critically ill children (Photo courtesy of Unsplash)

When a patient in the pediatric intensive care unit (PICU) develops a fever, physicians often routinely order a blood culture to identify the cause, particularly if they have reason to worry about sepsis, a life-threatening condition that occurs when chemicals released by immune system cells in the bloodstream to fight an infection trigger inflammation and shock throughout the body. However, repeated blood draws along with the use of antibiotics while awaiting culture results contribute to a rise in antibiotic resistance, leading to additional testing and extending the hospital length of stay. Now, researchers have developed and demonstrated the safety of a decision support program that appears to substantially reduce the number of blood draws in the PICU, and is likely to reduce antibiotic prescriptions without increasing the risk of sepsis.

The new study which was a national collaborative of 14 institutions and their experts, including researchers at Johns Hopkins University (Baltimore, MD, USA), builds on programs already in place that have safely reduced the use of other diagnostic tests, such as urine cultures. According to data from the U.S. Centers for Disease Control and Prevention, about 30% of antibiotics used in hospitals are unnecessary or prescribed incorrectly. Previous studies from other researchers have found that more than half of patients in the PICU often receive antibiotics for symptoms such as fever that may arise from noninfectious illnesses or even weaning from some medications.

In their study, the research team at Johns Hopkins Children’s Center led a national multidisciplinary collaborative of experts in pediatric infectious diseases, critical care medicine, quality improvement and other fields called BrighT STAR (Testing STewardship to reduce Antibiotic Resistance). The goal was to explore and compare existing studies and practices, and produce guidance recommendations to reduce blood draws in patients with low suspicion or risk for sepsis, and to measure the impact of the algorithm on blood culture rates, broad-spectrum antibiotic use and other patient outcomes. The 14 participating sites were diverse with respect to institution size, patient population and geographic area. Johns Hopkins Medicine investigators provided each site, which had its own team of experts, with a pre-implementation assessment tool while coaching them to launch their own quality improvement programs and strategies to execute the plans.

While the composition of the clinical support tools varied, each institution sought to standardize practices across its unit and reduce variability in decisions in ordering blood cultures, as well as highlight patient safety considerations. Blood culture rates, along with other measures, were tracked and reported monthly. The coordinating team held regular calls with individual sites and the larger collaborative throughout all steps of the project, conducted between 2017 and 2020.

In the 24-month period prior to implementation of the quality improvement algorithms, 41,731 blood cultures were performed at all 14 sites, compared with 22,408 cultures in the 18-month post-implementation period. Across sites, the median blood culture rate dropped from 146 per 1,000 patient days/month before implementation to 99 per 1,000 patient days/month after. Overall, 13 of 14 sites reduced their blood culture rates in the post-implementation period between 15% and 58%. Across the 14 sites, the blood culture rate was reduced by an average of 34% between the study’s pre- and post-implementation time frames (156.9 blood cultures per 1,000 patient days/month to 104.1 blood cultures per 1,000 patient days/month).

In the 11 sites that reported on antibiotic use, results showed a 13% overall average reduction in the amount of antibiotics prescribed (506.0 versus 440.3 total days per 1,000 patient days/month). At all 14 sites, central line-associated bloodstream infections decreased by 36% (1.79 to 1.14 per 1,000 central line days/month). There was no significant change in the rates of one of the most frequent and dangerous hospital-acquired infections, Clostridioides difficile (0.38 vs. 0.36 infections per 1,000 patient days/month). Mortality rates, length of stay and readmission in the PICU, as well as overall hospital readmissions, were similar before and after program implementation.

The research team has cautioned that the study may have missed instances in which antibiotics were prescribed without collecting blood cultures, which could have increased the amount prescribed. Also, all sites enrolled in the study had clinicians and others experienced in quality improvement. The researchers additionally say their analyses do not account for variations in individual site implementation plans. However, they believe their concept will help change clinician decision-making and, ultimately, benefit patients. The researchers are seeking to expand and implement a similar approach at all hospitals across the nation. They are also investigating ways to scale this concept to other hospital units, including those caring for adults.

“These findings suggest that multidisciplinary efforts to standardize blood culture collection and avoid unnecessary testing in the PICU can be done successfully and safely in diverse settings, and that reducing blood culture use can, in turn, reduce broad-spectrum antibiotic use,” said pediatric infectious diseases specialist Aaron Milstone, M.D., M.H.S., who is also a professor of pediatrics at the Johns Hopkins University School of Medicine and an expert on systems designed to prevent hospital-acquired infections and improve patient safety.

Related Links:
Johns Hopkins University 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.